Treace Medical Concepts Reports Q1 2025 Financial Results

Treace Medical Concepts, Inc. ( (TMCI) ) has released its Q1 earnings. Here is a breakdown of the information Treace Medical Concepts, Inc. presented to its investors.

Treace Medical Concepts, Inc. is a medical technology company specializing in innovative surgical solutions for bunion and midfoot deformities, primarily through its Lapiplasty® and Adductoplasty® procedures. In its first-quarter 2025 financial results, Treace reported a revenue of $52.6 million, marking a 3% increase compared to the same period in 2024. The company also improved its net loss by 15% to $15.9 million and adjusted EBITDA by 53% to $3.8 million. Key strategic developments include the expansion of its bunion technology portfolio with new systems and the announcement of positive clinical data for its procedures. Treace’s gross profit for the quarter was $41.9 million with a gross margin of 79.7%, while operating expenses decreased to $57.5 million. The company maintains a strong liquidity position with $98.6 million in total liquidity. Looking ahead, Treace reaffirms its full-year 2025 revenue guidance of $224 million to $230 million, expecting growth of 7% to 10%, and anticipates breakeven adjusted EBITDA for the year, reflecting confidence in its expanding product portfolio and market leadership.